<DOC>
	<DOCNO>NCT00001908</DOCNO>
	<brief_summary>Asthma chronic inflammatory disorder airway characterize reversible airflow obstruction . Fourteen million people ( 6.4 % ) United States report asthma , 1980 1994 prevalence self-reported asthma United States increase 75 % . Interleukin-4 ( IL-4 ) play key role response promote IgE production , upregulating IgE receptor , upregulating adhesion receptor VCAM-1 , promote Th2 cell development promote mucus secretion . A soluble form receptor IL-4 ( IL-4R ) antagonist activity develop clinical use . Soluble IL-4R act compete endogenous cell bound IL-4R free IL-4 , thus inhibit IL-4 function . IL-4 required development allergen specific Th2 memory cell . Less well understood factor require maintenance Th2 responses . The maintenance polarize Th2 response allergens postulate require IL-4 , act anti-apoptotic/survival factor differentiate naive allergen specific T cell Th2 phenotype . Subjects sIL-4 therapy represent unique patient group posse allergen specific Th2 cell , capacity IL-4 promote Th2 cell survival differentiation block . This single site adjunct study propose study subject age 14 year old enrol NIH Clinical Center multicenter trial IL-4R moderate severe asthma ( Phase II Efficacy Study Aerosolized Recombinant Human IL-4 Receptor Asthma ) . A maximum 40 subject enrol . We hypothesize effective blocking Th2 priming would result decreased frequency allergen specific Th2 cell well mitogen activate Th2 cell . Determination fate Th2 cell response long term IL-4R therapy may important implication future development anti-cytokine therapy well understand T cell biology allergic disease asthma .</brief_summary>
	<brief_title>T Cell Cytokine Changes During IL-4 Receptor Treatment Asthma</brief_title>
	<detailed_description>Asthma chronic inflammatory disorder airway characterize reversible airflow obstruction . Fourteen million people ( 6.4 % ) United States report asthma , 1980 1994 prevalence self-reported asthma United States increase 75 % . Interleukin-4 ( IL-4 ) play key role response promote IgE production , upregulating IgE receptor , upregulating adhesion receptor VCAM-1 , promote Th2 cell development promote mucus secretion . A soluble form receptor IL-4 ( IL-4R ) antagonist activity develop clinical use . Soluble IL-4R act compete endogenous cell bound IL-4R free IL-4 , thus inhibit IL-4 function . IL-4 required development allergen specific Th2 memory cell . Less well understood factor require maintenance Th2 responses . The maintenance polarize Th2 response allergens postulate require IL-4 , act anti-apoptotic/survival factor differentiate naive allergen specific T cell Th2 phenotype . Subjects sIL-4 therapy represent unique patient group posse allergen specific Th2 cell , capacity IL-4 promote Th2 cell survival differentiation block . This single site adjunct study propose study subject age 14 year old enrol NIH Clinical Center multicenter trial IL-4R moderate severe asthma ( Phase II Efficacy Study Aerosolized Recombinant Human IL-4 Receptor Asthma ) . A maximum 40 subject enrol . We hypothesize effective blocking Th2 priming would result decreased frequency allergen specific Th2 cell well mitogen activate Th2 cell . Determination fate Th2 cell response long term IL-4R therapy may important implication future development anti-cytokine therapy well understand T cell biology allergic disease asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Patients must 14 year age old . Must participate 99I0115 `` Phase II Efficacy Study Aerosolized Recombinant Human IL4 Receptor Asthma '' . If young 18 year old , must weigh 50 kg . Must HIV seronegativity . Must hemoglobin le 12 g/dL .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Interleukin</keyword>
	<keyword>Immunomodulator</keyword>
	<keyword>Th2</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Asthma</keyword>
</DOC>